Other immunotherapeutic approaches used in prostate cancer clinical trials include checkpoint inhibitory antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4), such as ipilimumab, and programmed cell death protein 1 (PD-1), such as nivolumab or pembrolizumab. Here, PDCD1 is linked to prostate cancer.